FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1710268954> ?p ?o ?g. }

• W1710268954 endingPage "1503.e1" @default.
• W1710268954 startingPage "1495" @default.
• W1710268954 abstract "ObjectiveThe objective of this study was to report 30-day results from a prospective, nonrandomized, multicenter trial that evaluated the safety and effectiveness of the Zenith Alpha thoracic endovascular graft (Cook Medical, Bloomington, Ind) for treatment of blunt thoracic aortic injuries (BTAIs).MethodsEligible patients with BTAIs (grade II to grade IV) in the descending thoracic aorta were treated with the Zenith Alpha device, which is available in smaller graft diameters (starting at 18 mm) and lower profile delivery systems (starting at 16F) than currently available thoracic endografts. The device (nitinol stents and polyester graft material) accommodates a tighter aortic curvature (radius of 20 mm) than the predicate Zenith TX2 Pro-Form. Follow-up clinical and imaging evaluations were performed at 30 days, at 6 and 12 months, and annually thereafter through 5 years. The primary end point was 30-day mortality.ResultsBetween January 2013 and May 2014, 50 patients (44 men; mean age, 43 ± 19 years; range, 18-89 years) were treated with the Zenith Alpha device at 17 U.S. sites. The mean Injury Severity Score was 31 ± 14 (range, 3-66). Technical success was achieved in 100% of patients, with 0% intraoperative mortality. Device access was entirely percutaneous in 22 patients (44%). Smaller size grafts (18-24 mm) were used in 15 patients (30%). The mean procedure time was 85 ± 44 minutes (range, 34-278 minutes), and mean blood loss was 103 ± 145 mL (range, 0-1000 mL). The 30-day mortality rate was 2%; one patient died 24 days after the procedure of respiratory failure related to associated injuries and not to the device or procedure as adjudicated by an independent Clinical Events Committee (CEC). One patient experienced a stroke 7 days after the procedure (cause undetermined by the CEC), and one patient underwent reintervention for a site-reported proximal type I endoleak (core laboratory reported unknown endoleak type) at 30 days after the procedure. There have been no conversions to open surgical repair, paraplegia, or aortic rupture within 30 days.ConclusionsShort-term results indicate that the Zenith Alpha thoracic endovascular graft appears safe and effective for the treatment of BTAIs. This low-profile device enables complete percutaneous repair in a large percentage of patients and can achieve high rates of technical success and very low rates of aortic injury-related mortality within 30 days. The objective of this study was to report 30-day results from a prospective, nonrandomized, multicenter trial that evaluated the safety and effectiveness of the Zenith Alpha thoracic endovascular graft (Cook Medical, Bloomington, Ind) for treatment of blunt thoracic aortic injuries (BTAIs). Eligible patients with BTAIs (grade II to grade IV) in the descending thoracic aorta were treated with the Zenith Alpha device, which is available in smaller graft diameters (starting at 18 mm) and lower profile delivery systems (starting at 16F) than currently available thoracic endografts. The device (nitinol stents and polyester graft material) accommodates a tighter aortic curvature (radius of 20 mm) than the predicate Zenith TX2 Pro-Form. Follow-up clinical and imaging evaluations were performed at 30 days, at 6 and 12 months, and annually thereafter through 5 years. The primary end point was 30-day mortality. Between January 2013 and May 2014, 50 patients (44 men; mean age, 43 ± 19 years; range, 18-89 years) were treated with the Zenith Alpha device at 17 U.S. sites. The mean Injury Severity Score was 31 ± 14 (range, 3-66). Technical success was achieved in 100% of patients, with 0% intraoperative mortality. Device access was entirely percutaneous in 22 patients (44%). Smaller size grafts (18-24 mm) were used in 15 patients (30%). The mean procedure time was 85 ± 44 minutes (range, 34-278 minutes), and mean blood loss was 103 ± 145 mL (range, 0-1000 mL). The 30-day mortality rate was 2%; one patient died 24 days after the procedure of respiratory failure related to associated injuries and not to the device or procedure as adjudicated by an independent Clinical Events Committee (CEC). One patient experienced a stroke 7 days after the procedure (cause undetermined by the CEC), and one patient underwent reintervention for a site-reported proximal type I endoleak (core laboratory reported unknown endoleak type) at 30 days after the procedure. There have been no conversions to open surgical repair, paraplegia, or aortic rupture within 30 days. Short-term results indicate that the Zenith Alpha thoracic endovascular graft appears safe and effective for the treatment of BTAIs. This low-profile device enables complete percutaneous repair in a large percentage of patients and can achieve high rates of technical success and very low rates of aortic injury-related mortality within 30 days." @default.
• W1710268954 created "2016-06-24" @default.
• W1710268954 creator A5010522731 @default.
• W1710268954 creator A5024926727 @default.
• W1710268954 creator A5027059295 @default.
• W1710268954 creator A5029125854 @default.
• W1710268954 creator A5035634311 @default.
• W1710268954 creator A5039846501 @default.
• W1710268954 creator A5040412256 @default.
• W1710268954 creator A5049280662 @default.
• W1710268954 creator A5054416822 @default.
• W1710268954 creator A5058595902 @default.
• W1710268954 creator A5060880109 @default.
• W1710268954 creator A5064263803 @default.
• W1710268954 creator A5066993884 @default.
• W1710268954 creator A5072717081 @default.
• W1710268954 creator A5073435349 @default.
• W1710268954 creator A5078109993 @default.
• W1710268954 creator A5087281876 @default.
• W1710268954 creator A5091649309 @default.
• W1710268954 date "2015-12-01" @default.
• W1710268954 modified "2023-09-29" @default.
• W1710268954 title "Endovascular repair for blunt thoracic aortic injury using the Zenith Alpha low-profile device" @default.
• W1710268954 cites W1966683692 @default.
• W1710268954 cites W1989445471 @default.
• W1710268954 cites W2007852601 @default.
• W1710268954 cites W2040530721 @default.
• W1710268954 cites W2053735462 @default.
• W1710268954 cites W2066272548 @default.
• W1710268954 cites W2068288496 @default.
• W1710268954 cites W2069144345 @default.
• W1710268954 cites W2094814890 @default.
• W1710268954 cites W2113129487 @default.
• W1710268954 cites W2151621499 @default.
• W1710268954 doi "https://doi.org/10.1016/j.jvs.2015.07.098" @default.
• W1710268954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26391458" @default.
• W1710268954 hasPublicationYear "2015" @default.
• W1710268954 type Work @default.
• W1710268954 sameAs 1710268954 @default.
• W1710268954 citedByCount "17" @default.
• W1710268954 countsByYear W17102689542017 @default.
• W1710268954 countsByYear W17102689542019 @default.
• W1710268954 countsByYear W17102689542020 @default.
• W1710268954 countsByYear W17102689542021 @default.
• W1710268954 countsByYear W17102689542022 @default.
• W1710268954 countsByYear W17102689542023 @default.
• W1710268954 crossrefType "journal-article" @default.
• W1710268954 hasAuthorship W1710268954A5010522731 @default.
• W1710268954 hasAuthorship W1710268954A5024926727 @default.
• W1710268954 hasAuthorship W1710268954A5027059295 @default.
• W1710268954 hasAuthorship W1710268954A5029125854 @default.
• W1710268954 hasAuthorship W1710268954A5035634311 @default.
• W1710268954 hasAuthorship W1710268954A5039846501 @default.
• W1710268954 hasAuthorship W1710268954A5040412256 @default.
• W1710268954 hasAuthorship W1710268954A5049280662 @default.
• W1710268954 hasAuthorship W1710268954A5054416822 @default.
• W1710268954 hasAuthorship W1710268954A5058595902 @default.
• W1710268954 hasAuthorship W1710268954A5060880109 @default.
• W1710268954 hasAuthorship W1710268954A5064263803 @default.
• W1710268954 hasAuthorship W1710268954A5066993884 @default.
• W1710268954 hasAuthorship W1710268954A5072717081 @default.
• W1710268954 hasAuthorship W1710268954A5073435349 @default.
• W1710268954 hasAuthorship W1710268954A5078109993 @default.
• W1710268954 hasAuthorship W1710268954A5087281876 @default.
• W1710268954 hasAuthorship W1710268954A5091649309 @default.
• W1710268954 hasBestOaLocation W17102689541 @default.
• W1710268954 hasConcept C105698618 @default.
• W1710268954 hasConcept C119060515 @default.
• W1710268954 hasConcept C126838900 @default.
• W1710268954 hasConcept C127313418 @default.
• W1710268954 hasConcept C141071460 @default.
• W1710268954 hasConcept C160022790 @default.
• W1710268954 hasConcept C168563851 @default.
• W1710268954 hasConcept C203092338 @default.
• W1710268954 hasConcept C2776864027 @default.
• W1710268954 hasConcept C2779980429 @default.
• W1710268954 hasConcept C2780813298 @default.
• W1710268954 hasConcept C2989005 @default.
• W1710268954 hasConcept C2994150672 @default.
• W1710268954 hasConcept C53970728 @default.
• W1710268954 hasConcept C62649853 @default.
• W1710268954 hasConcept C71924100 @default.
• W1710268954 hasConceptScore W1710268954C105698618 @default.
• W1710268954 hasConceptScore W1710268954C119060515 @default.
• W1710268954 hasConceptScore W1710268954C126838900 @default.
• W1710268954 hasConceptScore W1710268954C127313418 @default.
• W1710268954 hasConceptScore W1710268954C141071460 @default.
• W1710268954 hasConceptScore W1710268954C160022790 @default.
• W1710268954 hasConceptScore W1710268954C168563851 @default.
• W1710268954 hasConceptScore W1710268954C203092338 @default.
• W1710268954 hasConceptScore W1710268954C2776864027 @default.
• W1710268954 hasConceptScore W1710268954C2779980429 @default.
• W1710268954 hasConceptScore W1710268954C2780813298 @default.
• W1710268954 hasConceptScore W1710268954C2989005 @default.
• W1710268954 hasConceptScore W1710268954C2994150672 @default.
• W1710268954 hasConceptScore W1710268954C53970728 @default.
• W1710268954 hasConceptScore W1710268954C62649853 @default.
• W1710268954 hasConceptScore W1710268954C71924100 @default.

• next